RAPT Therapeutics (RAPT) Operating Leases: 2022-2024
Historic Operating Leases for Therapeutics (RAPT) over the last 3 years, with Sep 2024 value amounting to $2.6 million.
- Therapeutics' Operating Leases fell 48.80% to $2.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.6 million, marking a year-over-year decrease of 48.80%. This contributed to the annual value of $4.5 million for FY2023, which is 34.62% down from last year.
- Latest data reveals that Therapeutics reported Operating Leases of $2.6 million as of Q3 2024, which was down 17.79% from $3.2 million recorded in Q2 2024.
- Therapeutics' Operating Leases' 5-year high stood at $7.1 million during Q1 2022, with a 5-year trough of $2.6 million in Q3 2024.
- Moreover, its 3-year median value for Operating Leases was $5.7 million (2023), whereas its average is $5.3 million.
- Data for Therapeutics' Operating Leases shows a maximum YoY crashed of 48.80% (in 2024) over the last 5 years.
- Quarterly analysis of 3 years shows Therapeutics' Operating Leases stood at $6.8 million in 2022, then plummeted by 34.62% to $4.5 million in 2023, then crashed by 48.80% to $2.6 million in 2024.
- Its last three reported values are $2.6 million in Q3 2024, $3.2 million for Q2 2024, and $3.8 million during Q1 2024.